2020 Q1 Form 10-Q Financial Statement
#000156459020024390 Filed on May 12, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $4.140M | $7.010M |
| YoY Change | -40.94% | 1354.36% |
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $5.650M | $4.940M |
| YoY Change | 14.37% | 69.76% |
| % of Gross Profit | ||
| Research & Development | $20.63M | $8.454M |
| YoY Change | 144.03% | 26.37% |
| % of Gross Profit | ||
| Depreciation & Amortization | $618.0K | $177.0K |
| YoY Change | 249.15% | 145.83% |
| % of Gross Profit | ||
| Operating Expenses | $26.28M | $8.454M |
| YoY Change | 210.86% | -11.91% |
| Operating Profit | ||
| YoY Change | ||
| Interest Expense | $472.0K | $210.0K |
| YoY Change | 124.76% | -28.81% |
| % of Operating Profit | ||
| Other Income/Expense, Net | ||
| YoY Change | ||
| Pretax Income | -$22.01M | -$6.168M |
| YoY Change | 256.89% | -29.18% |
| Income Tax | $5.000K | $0.00 |
| % Of Pretax Income | ||
| Net Earnings | -$22.02M | -$6.168M |
| YoY Change | 256.97% | -29.22% |
| Net Earnings / Revenue | -531.84% | -87.99% |
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$482.4K | -$167.9K |
| COMMON SHARES | ||
| Basic Shares Outstanding | 45.65M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $105.0M | $83.58M |
| YoY Change | 25.64% | 69.52% |
| Cash & Equivalents | $34.44M | $37.86M |
| Short-Term Investments | $70.50M | $45.72M |
| Other Short-Term Assets | $8.400M | $5.085M |
| YoY Change | 65.19% | 3431.25% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | $1.300M | $300.0K |
| Other Receivables | $9.400M | $0.00 |
| Total Short-Term Assets | $124.2M | $91.00M |
| YoY Change | 36.48% | 65.76% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $19.30M | $18.20M |
| YoY Change | 6.05% | 323.26% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $3.000M | |
| YoY Change | ||
| Other Assets | $4.617M | $4.783M |
| YoY Change | -3.47% | 241.64% |
| Total Long-Term Assets | $36.54M | -$86.82M |
| YoY Change | -142.09% | -368.79% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $124.2M | $91.00M |
| Total Long-Term Assets | $36.54M | -$86.82M |
| Total Assets | $160.7M | $4.180M |
| YoY Change | 3745.53% | -95.21% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $1.770M | $1.582M |
| YoY Change | 11.88% | -45.45% |
| Accrued Expenses | $11.53M | $6.900M |
| YoY Change | 67.12% | 146.43% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | $0.00 | $0.00 |
| YoY Change | ||
| Total Short-Term Liabilities | $43.84M | $28.10M |
| YoY Change | 56.0% | 132.23% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $2.900M | $3.200M |
| YoY Change | -9.38% | 6.7% |
| Other Long-Term Liabilities | $30.30M | $374.0K |
| YoY Change | 8001.6% | -54.83% |
| Total Long-Term Liabilities | $33.20M | $374.0K |
| YoY Change | 8777.01% | -90.23% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $43.84M | $28.10M |
| Total Long-Term Liabilities | $33.20M | $374.0K |
| Total Liabilities | $77.00M | $4.705M |
| YoY Change | 1536.56% | -71.13% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | ||
| YoY Change | ||
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $83.77M | $96.14M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $160.7M | $140.6M |
| YoY Change | 14.3% | 61.24% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$22.02M | -$6.168M |
| YoY Change | 256.97% | -29.22% |
| Depreciation, Depletion And Amortization | $618.0K | $177.0K |
| YoY Change | 249.15% | 145.83% |
| Cash From Operating Activities | -$18.15M | -$10.98M |
| YoY Change | 65.35% | 22.19% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $938.0K | $625.0K |
| YoY Change | 50.08% | -63.64% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$32.01M | -$35.30M |
| YoY Change | -9.32% | |
| Cash From Investing Activities | -$32.95M | -$35.92M |
| YoY Change | -8.27% | 1989.59% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $0.00 | -$8.000K |
| YoY Change | -100.0% | |
| Debt Paid & Issued, Net | $200.0K | $0.00 |
| YoY Change | -100.0% | |
| Cash From Financing Activities | 93.00K | 30.00K |
| YoY Change | 210.0% | -97.19% |
| NET CHANGE | ||
| Cash From Operating Activities | -18.15M | -10.98M |
| Cash From Investing Activities | -32.95M | -35.92M |
| Cash From Financing Activities | 93.00K | 30.00K |
| Net Change In Cash | -51.01M | -46.87M |
| YoY Change | 8.84% | 386.41% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$18.15M | -$10.98M |
| Capital Expenditures | $938.0K | $625.0K |
| Free Cash Flow | -$19.09M | -$11.60M |
| YoY Change | 64.53% | 8.4% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
9617000 | |
| CY2019Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
1366000 | |
| CY2019Q4 | us-gaap |
Liabilities
Liabilities
|
71174000 | |
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
0 | |
| CY2019Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | |
| CY2019Q4 | us-gaap |
Long Term Debt Noncurrent
LongTermDebtNoncurrent
|
2940000 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
19301000 | |
| CY2020Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
4617000 | |
| CY2020Q1 | us-gaap |
Assets
Assets
|
160743000 | |
| CY2020Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1770000 | |
| CY2020Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
11531000 | |
| CY2020Q1 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
11465000 | |
| CY2020Q1 | mtem |
Deferred Revenue Related Parties Current
DeferredRevenueRelatedPartiesCurrent
|
8773000 | |
| CY2019Q4 | mtem |
Deferred Revenue Related Parties Current
DeferredRevenueRelatedPartiesCurrent
|
8780000 | |
| CY2019Q4 | mtem |
Other Liabilities Related Parties Current
OtherLiabilitiesRelatedPartiesCurrent
|
0 | |
| CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
43836000 | |
| CY2020Q1 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
14523000 | |
| CY2020Q1 | mtem |
Deferred Revenue Long Term Related Parties Noncurrent
DeferredRevenueLongTermRelatedPartiesNoncurrent
|
1355000 | |
| CY2019Q4 | mtem |
Deferred Revenue Long Term Related Parties Noncurrent
DeferredRevenueLongTermRelatedPartiesNoncurrent
|
441000 | |
| CY2019Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
11682000 | |
| CY2020Q1 | mtem |
Other Liabilities Related Parties Current
OtherLiabilitiesRelatedPartiesCurrent
|
7754000 | |
| CY2020Q1 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
2543000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
3010000 | |
| CY2019Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
2849000 | |
| CY2019Q4 | mtem |
Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
|
5774000 | |
| CY2019Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
17000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
105528000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
123977000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
1510000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
125487000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
123995000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
1510000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
0 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
|
1300000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
|
3000000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
|
102518000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
|
3010000 | |
| CY2019Q4 | mtem |
Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
|
4521000 | |
| CY2019Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
46000 | |
| CY2019Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
267089000 | |
| CY2019Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
18000 | |
| CY2019Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-164125000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
103028000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.48 | |
| CY2019Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.17 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
45649065 | |
| CY2019Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
36738993 | |
| CY2019Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
174202000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
2000000 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
250 | |
| CY2019Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
250 | |
| CY2019Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
45589157 | |
| CY2019Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
45589157 | |
| CY2020Q1 | us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
4141000 | |
| CY2019Q1 | us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
7008000 | |
| CY2019Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8454000 | |
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4935000 | |
| CY2020Q1 | mtem |
Interest And Other Expense Net
InterestAndOtherExpenseNet
|
348000 | |
| CY2020Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | |
| CY2019Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
4000 | |
| CY2020Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-22013000 | |
| CY2019Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6168000 | |
| CY2020Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
5000 | |
| CY2019Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
618000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
177000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2192000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1360000 | |
| CY2020Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
148000 | |
| CY2019Q1 | us-gaap |
Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
|
105000 | |
| CY2020Q1 | us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
32000 | |
| CY2019Q1 | us-gaap |
Asset Retirement Obligation Accretion Expense
AssetRetirementObligationAccretionExpense
|
11000 | |
| CY2020Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | |
| CY2019Q1 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
0 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
1409000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-239000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
|
892000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Receivable Related Parties
IncreaseDecreaseInAccountsReceivableRelatedParties
|
55000 | |
| CY2020Q1 | mtem |
Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
|
2341000 | |
| CY2019Q1 | mtem |
Increase Decrease In Grants Revenue Receivable
IncreaseDecreaseInGrantsRevenueReceivable
|
2000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-293000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
338000 | |
| CY2020Q1 | mtem |
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
|
-60000 | |
| CY2019Q1 | mtem |
Increase Decrease In Operating Lease Right Of Use Assets And Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsAndLiabilities
|
0 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
260000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
802000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-3912000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
622000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
1746000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-204000 | |
| CY2020Q1 | mtem |
Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
|
7754000 | |
| CY2019Q1 | mtem |
Increase Decrease In Other Noncurrent Liabilities Related Parties
IncreaseDecreaseInOtherNoncurrentLiabilitiesRelatedParties
|
0 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1467000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
0 | |
| CY2020Q1 | mtem |
Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
|
907000 | |
| CY2019Q1 | mtem |
Increase Decrease In Deferred Revenue Related Parties Current
IncreaseDecreaseInDeferredRevenueRelatedPartiesCurrent
|
-7529000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-18149000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-10976000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
938000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
625000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
50463000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
36588000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
18450000 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
1293000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-32951000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-35920000 | |
| CY2020Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
200000 | |
| CY2019Q1 | us-gaap |
Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
|
0 | |
| CY2020Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
300000 | |
| CY2019Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
38000 | |
| CY2019Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
-8000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
93000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
30000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-51007000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-46866000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
88451000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
87721000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
37444000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
40855000 | |
| CY2019Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
37855000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
3000000 | |
| CY2019Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
3000000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsMember | |
| CY2019Q1 | us-gaap |
Restricted Cash And Cash Equivalents Asset Statement Of Financial Position Extensible List
RestrictedCashAndCashEquivalentsAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherAssetsMember | |
| CY2020Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
163000 | |
| CY2019Q1 | us-gaap |
Interest Paid Net
InterestPaidNet
|
174000 | |
| CY2020Q1 | mtem |
Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
|
944000 | |
| CY2019Q1 | mtem |
Fixed Asset Additions In Accounts Payable And Accrued Expenses
FixedAssetAdditionsInAccountsPayableAndAccruedExpenses
|
0 | |
| CY2020Q1 | mtem |
Noncash Right Of Use Asset Obtained In Exchange For Operating Lease Obligations
NoncashRightOfUseAssetObtainedInExchangeForOperatingLeaseObligations
|
0 | |
| CY2019Q1 | mtem |
Noncash Right Of Use Asset Obtained In Exchange For Operating Lease Obligations
NoncashRightOfUseAssetObtainedInExchangeForOperatingLeaseObligations
|
7234000 | |
| CY2020Q1 | mtem |
Noncash Adoption Of Accounting Standards Codification
NoncashAdoptionOfAccountingStandardsCodification
|
0 | |
| CY2019Q1 | mtem |
Noncash Adoption Of Accounting Standards Codification
NoncashAdoptionOfAccountingStandardsCodification
|
4179000 | |
| CY2020Q1 | mtem |
Noncash Investing And Financing Activities
NoncashInvestingAndFinancingActivities
|
944000 | |
| CY2019Q1 | mtem |
Noncash Investing And Financing Activities
NoncashInvestingAndFinancingActivities
|
11413000 | |
| CY2020Q1 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain amounts in the prior year’s presentation have been reclassified to conform to the current presentation. The condensed consolidated balance sheet at December 31, 2019 included herein was derived from the audited financial statements at that date, but includes a reclassification of $8.8 million from Deferred revenue, current to Deferred revenue, current, related party and $0.4 million from Deferred revenue, non-current to Deferred revenue, non-current, related party in order to conform to current period presentation. The condensed consolidated statements of cash flow for the three months ended March 31, 2019 included herein includes a reclassification of $7.5 million from Deferred revenue to Deferred revenue, related party. </p> | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments, long term debt and accounts receivable.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.42%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash and cash equivalents are with two major financial institutions in the United States. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.42%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company performs an ongoing credit evaluation of its strategic partners’ financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. Vertex accounted for approximately 35% and 0% of total revenues for the three months ended March 31, 2020 and 2019, respectively. The Company’s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Ltd. (“Takeda”). Takeda accounted for approximately 8% and 92% of total revenues for the three months ended March 31, 2020 and 2019, respectively.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.42%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug or biologic candidates developed by the Company may require approvals or clearances from the U.S. Food and Drug Administration (“FDA”) or international regulatory agencies prior to commercial sales. There can be no assurance that the Company’s drug or biologic candidates will receive any of the required approvals or clearances. If the Company were to be denied approval or clearance or any such approval or clearance were to be delayed, it would have a material adverse impact on the Company.</p> | |
| CY2019Q4 | mtem |
Deferred Revenue Related Parties Noncurrent
DeferredRevenueRelatedPartiesNoncurrent
|
400000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
108000000 | |
| CY2020Q1 | mtem |
Research And Development Revenues From Collaboration Agreements
ResearchAndDevelopmentRevenuesFromCollaborationAgreements
|
1800000 | |
| CY2020Q1 | us-gaap |
Deferred Revenue
DeferredRevenue
|
36100000 | |
| CY2019Q4 | us-gaap |
Deferred Revenue
DeferredRevenue
|
36700000 | |
| CY2020Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
105528000 | |
| CY2020Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
70544000 | |
| CY2020Q1 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
3010000 | |
| CY2019Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
39633000 | |
| CY2019Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
1510000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
|
102247000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
105247000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
125505000 | |
| CY2020Q1 | mtem |
Accrued General And Administrative Current
AccruedGeneralAndAdministrativeCurrent
|
2034000 | |
| CY2020Q1 | mtem |
Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
|
1696000 | |
| CY2019Q4 | mtem |
Accrued Clinical Trial Related Costs Current
AccruedClinicalTrialRelatedCostsCurrent
|
1383000 | |
| CY2020Q1 | mtem |
Accrued Non Clinical Research And Manufacturing Operations Current
AccruedNonClinicalResearchAndManufacturingOperationsCurrent
|
6119000 | |
| CY2020Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1659000 | |
| CY2020Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
23000 | |
| CY2020Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
23334000 | |
| CY2019Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
21451000 | |
| CY2020Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
4033000 | |
| CY2019Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
3293000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
700000 | |
| CY2019Q1 | us-gaap |
Depreciation
Depreciation
|
400000 | |
| CY2020Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
3700000 | |
| CY2019Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
3700000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
561000 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
130000 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
691000 | |
| CY2020Q1 | us-gaap |
Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
|
2000 | |
| CY2020Q1 | mtem |
Finance Lease Expense
FinanceLeaseExpense
|
2000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
31800000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
1731000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
12963000 | |
| CY2020Q1 | mtem |
Finance Lease Right Of Use Asset Gross
FinanceLeaseRightOfUseAssetGross
|
77000 | |
| CY2020Q1 | us-gaap |
Finance Lease Interest Expense
FinanceLeaseInterestExpense
|
0 | |
| CY2020Q1 | mtem |
Finance Lease Liability Payments Due Year Six
FinanceLeaseLiabilityPaymentsDueYearSix
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
|
12000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability
FinanceLeaseLiability
|
12000 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
515000 | |
| CY2020Q1 | us-gaap |
Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Principal Payments
FinanceLeasePrincipalPayments
|
7000 | |
| CY2020Q1 | mtem |
Upfront Fees Unamortized Balance Included In Prepaid Asset
UpfrontFeesUnamortizedBalanceIncludedInPrepaidAsset
|
2600000 | |
| CY2020Q1 | mtem |
Finance Lease Right Of Use Asset Accumulated Depreciation
FinanceLeaseRightOfUseAssetAccumulatedDepreciation
|
43000 | |
| CY2020Q1 | us-gaap |
Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
|
34000 | |
| CY2020Q1 | us-gaap |
Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
|
us-gaap:PropertyPlantAndEquipmentNet | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
|
12000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
us-gaap:OtherLiabilitiesCurrent | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P7Y | |
| CY2020Q1 | us-gaap |
Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
|
P7M6D | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0672 | |
| CY2020Q1 | us-gaap |
Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
|
0.0681 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
1895000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
2589000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
2650000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
1961000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
1474000 | |
| CY2020Q1 | mtem |
Lessee Operating Lease Liability Payments Due Year Six
LesseeOperatingLeaseLiabilityPaymentsDueYearSix
|
1517000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
4246000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
16332000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
3369000 | |
| CY2020Q1 | mtem |
Lessee Operating Lease Liability Total Lease Payments Net Of Interest
LesseeOperatingLeaseLiabilityTotalLeasePaymentsNetOfInterest
|
12963000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
|
12000 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
|
0 | |
| CY2020Q1 | us-gaap |
Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
|
0 | |
| CY2020Q1 | us-gaap |
Contractual Obligation
ContractualObligation
|
43200000 | |
| CY2020Q1 | mtem |
Development Costs Sharing Percentage Exercised
DevelopmentCostsSharingPercentageExercised
|
0.50 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2192000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1361000 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
|
33100000 | |
| CY2020Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P2Y11M23D | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4743990 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1713706 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
114777 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
48457 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6294462 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2028825 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
6.37 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
14.51 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
2.62 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
11.07 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.62 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
6.17 | |
| CY2019 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y2M12D | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y6M | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P7Y2M12D | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
36500000 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
14800000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1300000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
100000 | |
| CY2020Q1 | mtem |
Employee Service Share Based Compensation Tax Benefit Realized From Exercise Of Stock Options1
EmployeeServiceShareBasedCompensationTaxBenefitRealizedFromExerciseOfStockOptions1
|
0 | |
| CY2019 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
22100000 |
